title: Late midtrimester medical pregnancy terminations: three different procedures with prostaglandin F2 alpha and laminaria tents.
abstract: One hundred twenty eight women underwent midtrimester induced abortion with: 1) combined regimen of intramniotic prostaglandin (PG) F2a injection and intracervical laminaria tents (group A, 50 women), 2) intramniotic PGF2a injection only (group B, 51 women) and 3) laminaria tents followed by intracervical PGF2a tablets insertion (group C, 27 women). The mean induction-abortion time (+/- SE) was 24.9 +/- 1.7 hours for group A, 28.2 +/- 2.2 hours for group B (p greater than 0.05) and 42.1 +/- 3.4 hours for group C, significantly longer than goup A and B (p less than 0.001 and p less than 0.01 respectively). In 48 hours 98% of the patients of group A, 90% of group B (p less than 0.05) and 59% of group C (p less than 0.001) completed the abortion procedure. Parous women of group A and B presented similar induction - abortion time, while in nulliparous the use of laminaria shortened the abortion procedure significantly (p less than 0.05). The complications rate was low. In conclusion, the intracervical PGF2a insertion is a simple but very slow abortion procedure with high failure rates. The intramniotic PGF2a injection is a successful method for late midtrimester medical pregnancy termination and the concurrent use of laminaria tents shortens the abortion procedure, particularly in nulliparous, reduces the number of prostaglandins' reinjections and increases the incidence of successful abortion within 48 hours.
authors.affiliation: 1st Department of Obstetrics and Gynecology, University of Athens, Greece.
authors.forename: I
authors.initials: I
authors.lastname: Papageorgiou
authors.forename: D
authors.initials: D
authors.lastname: Minaretzis
authors.forename: C
authors.initials: C
authors.lastname: Tsionou
authors.forename: S
authors.initials: S
authors.lastname: Michalas
mesh_terms: D000028:Abortion, Induced / Q000379:methods*; D000328:Adult; D000650:Amnion; D002584:Cervix Uteri; D015237:Dinoprost / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007267:Injections; D011183:Postoperative Complications; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D013607:Tablets
chemical_list: D013607:Tablets; D015237:Dinoprost